Pulmonary complications in children with primary immunodeficiencies and mid-regional pro-adrenomedullin (MR-proADM) levels
Project no. 20570 · Status: Kapanmış · 2019
Summary
The development of lower respiratory complications in primary immunodeficiencies characterized by recurrent infections significantly contributes to the morbidity and mortality and is clinically more important and specific in the evaluation of prognosis. The inflammatory response that develops throughout the clinical process can cause the release of biomarkers. The aim of this study was to investigate the distribution of lower respiratory tract complications in children with primary immunodeficiency and was to evaluate the inflammatory biomarker mid-regional proadrenomedullin (MR-proADM) levels. Plasma MR-proADM levels were studied with microELISA method in 155 cases who were divided into two groups; lower respiratory complicated (n: 52) and not complicated (n: 103). Complications were categorized into infectious (11 bronchitis-bronchiolitis, 9 pneumonia) and non-infectious (19 atelectasis, 5 bronchiectasis, 1 interstitial lung disease, 3 paranchimal nodule development, 4 chronic changes) groups. Mean MR-proADM was 192,4 ± 151,6 ng/L in respiratory complicated patients and 156,4 ± 122,3 ng/L in non- complicated patients. The difference between the two groups was not statistically significant (p: 0,175). Mean MR-ProADM level was 256,8 ± 147,7 ng/L in the infectious complicated group while it was 152,2 ± 141,7 ng/L in the non-infectious group. A statistically significant difference was observed between the two groups (p: 0,003). It was thought that more new studies are needed for the use of MR-proADM as a biomarker in chronic lung inflammation, which is found higher in infectious complicated patients and correlated with other inflammatory markers in non-infectious complicated patients.